Acute kidney injury and Primary Aldosteronism
Research Field
Vin-Cent Wu, group director of Taiwan Primary Aldosteronism Investigation (TAIPAI) and the National Taiwan University Study Group on Acute Renal Failure (NSARF), is a Professor of Medicine with career-long research in acute kidney injury and primary aldosteronism, and nephrology while being an activist for translational medicine.
Vin-Cent actively involved in the analysis of the largest database of acute kidney injury in the (NSARF and Consortium for Acute Kidney Injury and Renal Diseases (CAKs) strive to advance high-quality care in acute kidney injury (AKI) and aspires to plunge the worldwide increasing prevalence of chronic kidney disease (CKD) from the perspective of AKI-CKD transition. I am the committee of acute Disease Quality Initiative (ADQI) and Kidney Disease: Improving Global Outcomes (KDIGO).
Vin-Cent conducts the TAIPAI database, which is the largest registry about primary aldosteronism in Chinese people. This project is to improve the diagnosis of aldosteronism and aldosterone-related cardiovascular, psychosocial morbidity and mortality.
my research contributions have been recognized by Stanford University, where I was honored as one of the top 2% scientists from the years 2020 to 2023.Throughout my journey in the field of Life Sciences, I have been fortunate to receive esteemed awards and honors, recognition for my exceptional research contributions.
An exceptional milestone in my career was achieving the Outstanding Research Award for Excellent Contribution in Medical Research at the National Taiwan University Hospital, which highlighted the significance of team research accomplishments. In 2022, I was awarded the Silver Medal of the Symbol of National Quality (SNQ) in recognition of my achievements. The award undergoes rigorous and professional scientific validation. I am honored to have been awarded the 2023 Professor Wan-Yu Chen Research Award by the Taiwan Society of Nephrology. In recent years, this award has come to symbolize a lifetime achievement in the field of nephrology in Taiwan.
My dedication to scholarly publishing extends to my role as an editor, where I am privileged to serve on the editorial boards and as an invited editor for esteemed journals. Through these affiliations, I contribute to the dissemination of groundbreaking research and foster meaningful discussions among peers in the scientific community.
- more than 170, about aldosteronism , including Hypertension and Lancet End Meta.
(https://pubmed.ncbi.nlm.nih.gov/?term=Wu+V%2C+aldosteronism&sort=date)
- more than 135, about AKI, including JASN, Intensive Care Medicine. Critical care, Diabetic Care, and JAMA NET OPEN.
(https://pubmed.ncbi.nlm.nih.gov/?term=Wu+V%2C+kidney+injury%2C+&sort=date)
My research contributions have been recognized by Stanford University, where I was honored as one of the top 2% scientists from the years 2020 to 2023.Throughout my journey in the field of Life Sciences, I have been fortunate to receive esteemed awards and honors, recognition for my exceptional research contributions.
An exceptional milestone in my career was achieving the Outstanding Research Award for Excellent Contribution in Medical Research at the National Taiwan University Hospital, which highlighted the significance of team research accomplishments. In 2022, I was awarded the Silver Medal of the Symbol of National Quality (SNQ) in recognition of my achievements. The award undergoes rigorous and professional scientific validation. I am honored to have been awarded the 2023 Professor Wan-Yu Chen Research Award by the Taiwan Society of Nephrology. In recent years, this award has come to symbolize a lifetime achievement in the field of nephrology in Taiwan.
- Division of Nephrology, Primary Aldosteronism Center (PAC) of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
- Taiwan Primary Aldosteronism Investigation (TAIPAI) Study Group
- NSARF (National Taiwan University Hospital Study Group of ARF), and CAKS (Taiwan Consortium for Acute Kidney Injury and Renal Diseases), Taipei, Taiwan
Job Description
Furthermore, during tissue injury, specific forms of cellular fibronectin can be detected in serum, and interact with various cell types. This suggests that fibronectin, along with downstream mechanisms involving integrin activation, potentially associated with repair of acute kidney injury (AKI). To explore the potential role of integrin-mediated fibronectin regulation in AKI, transcriptomic analysis using next-generation sequencing techniques was performed. At 17 days post-injury, fibronectin and integrin α5 significantly increase compared to non-injured mice. However, downstream VEGF and cell proliferation protein did not show a corresponding elevation. Thus, it revealed that fibronectin might not effectively activate integrin α5β1during kidney injury. In this study, the PHSRN peptide of fibronectin is selected as a tool to investigate its role in cell repair by activating integrin α5β1 downstream regulation independently.
we will
(2) Using integrin α5 knock out mice, integrin α5 neutralized antibody or with integrin α5β1 inhibitor, PHSCN, also called ATN-161, to investigate mechanisms and specific contribution of integrin α5β1 pathway in attenuation of IRI AKI and AKD mice.
Preferred Intern Education Level
University education completed or
Completed undergraduate coursework
Skill sets or Qualities
just cell culture and Western blot analysis